Novo Nordisk (NVO) Stock Rallies as Wegovy Weight Loss Pill Launches in United States

TLDR Novo Nordisk stock climbed 5.4% Monday to $55.21 on volume 42% above average as Wegovy pill launched. The pill represents the first oral GLP-1 for obesity in the U.S., priced at $149 monthly for self-pay patients. Competitor Eli Lilly stock fell 3.6% after hours as investors anticipated market share shifts. Distribution began through CVS, [...]

The post Novo Nordisk (NVO) Stock Rallies as Wegovy Weight Loss Pill Launches in United States appeared first on Blockonomi.